What it's for (Indications)
- Ethinyloestradiol/drospirenone is primarily indicated for the prevention of pregnancy in women who choose an oral contraceptive method.
- Beyond its highly effective contraceptive properties, this medication is also FDA-approved for specific non-contraceptive uses.
- These include the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who desire oral contraception as their chosen method.
- Furthermore, it is indicated for the treatment of moderate acne vulgaris in women who have achieved menarche, are at least 14 years of age, and also desire an oral contraceptive for birth control.
- These additional indications leverage the unique properties of drospirenone, contributing to a broader therapeutic profile for suitable patients.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For contraception, PMDD, and acne, the recommended dosage of ethinyloestradiol/drospirenone (Yaz) involves taking one tablet daily for 28 consecutive days. The regimen consists of 24 active pink tablets, each containing 3 mg drospirenone and 0.02 mg ethinyloestradiol, followed by 4 inert white placebo tablets. It is crucial to take tablets in the order directed on the blister pack, preferably at the same time each day. A new blister pack should be started immediately after the last placebo tablet is taken, without any break between packs. If a dose is missed, specific instructions depending on the number of missed pills and week of the cycle must be followed to maintain contraceptive efficacy, often requiring backup contraception. Starting the first pack typically occurs on the first day of menstruation or the first Sunday following the start of menstruation. |
Safety & Warnings
Common Side Effects
- Patients using ethinyloestradiol/drospirenone may experience a range of side effects, varying in severity and frequency.
- Common adverse reactions include nausea, headache (including migraine), breast tenderness or pain, breakthrough bleeding or spotting, mood changes (including depression and mood swings), weight changes, and abdominal pain.
- More serious, albeit less common, side effects include an increased risk of venous thromboembolism (VTE), such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thrombotic events like stroke and myocardial infarction.
- Other significant risks involve hypertension, gallbladder disease, liver adenomas or carcinomas, and hyperkalemia due to drospirenone's antimineralocorticoid activity, especially in patients with renal impairment or those concurrently using potassium-sparing drugs.
- Patients should be counseled on recognizing symptoms of these serious conditions and seeking immediate medical attention if they occur.
Serious Warnings
- Black Box Warning: While combined hormonal contraceptives, including ethinyloestradiol/drospirenone, do not typically carry a formal 'Black Box Warning' label from the U.S. Food and Drug Administration in the same manner as some other drug classes, healthcare providers and patients must be aware of extremely serious and life-threatening risks that warrant prominent disclosure. The most critical safety warning associated with this medication is the significantly increased risk of serious cardiovascular events, including venous thromboembolism (VTE) such as deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as arterial thrombotic events like stroke and myocardial infarction. This risk is substantially amplified in women who smoke, especially those aged 35 years or older. Therefore, women over 35 who smoke are strongly advised against using ethinyloestradiol/drospirenone. This medication should also be used with extreme caution or is contraindicated in patients with other underlying risk factors for cardiovascular disease or thrombosis. Providers must carefully assess individual patient risk factors before prescribing.
- Ethinyloestradiol/drospirenone carries significant warnings, particularly concerning cardiovascular risks.
- The use of combined oral contraceptives (COCs) is associated with an increased risk of venous and arterial thrombotic and thromboembolic events.
- This risk is substantially elevated in women who smoke, especially those over 35 years of age; therefore, women over 35 who smoke should not use COCs.
- Additionally, drospirenone's antimineralocorticoid activity necessitates caution and monitoring in patients at risk for hyperkalemia, including those with renal impairment, adrenal insufficiency, hepatic dysfunction, or those using medications known to increase potassium levels.
- Other warnings include an increased risk of liver tumors, gallbladder disease, carbohydrate and lipid metabolism alterations, and elevated blood pressure.
- Patients should be advised about the importance of regular blood pressure monitoring and the immediate reporting of any signs or symptoms suggestive of thrombosis, severe headache, or liver problems.
How it Works (Mechanism of Action)
Ethinyloestradiol/drospirenone functions as a combined oral contraceptive primarily through the synergistic actions of its two hormonal components. The ethinyloestradiol component, a synthetic estrogen, works by suppressing follicle-stimulating hormone (FSH) release from the pituitary gland, thereby inhibiting ovarian follicular development and stabilizing the endometrial lining to reduce breakthrough bleeding. Drospirenone, a synthetic progestin, acts predominantly by suppressing luteinizing hormone (LH) secretion, which prevents ovulation. Additionally, drospirenone thickens cervical mucus, making it more difficult for sperm to penetrate and reach the ovum, and alters the endometrial lining, rendering it less receptive to implantation. Uniquely, drospirenone also exhibits antimineralocorticoid activity, which can help counteract estrogen-induced fluid retention, and antiandrogenic activity, contributing to its efficacy in treating acne and PMDD symptoms by modulating hormonal fluctuations. These combined actions provide highly effective contraception and therapeutic benefits for associated conditions.
Commercial Brands (Alternatives)
No other brands found for this formula.